SAN DIEGO, April 7, 2026 /PRNewswire/
-- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced its wholly-owned
subsidiary, Halozyme Hypercon, Inc., entered into a global exclusive collaboration and license agreement with
Vertex Pharmaceuticals Incorporated ("Vertex"). Under the collaboration, Vertex has licensed Halozyme's Hypercon™
technology for use in up to three drug targets. Hypercon™ is an innovative microparticle technology that allows
for hyperconcentration of drugs and biologics, thus reducing injection volume for the same dosage and enabling
convenient, at-home administration.
"This collaboration with Vertex underscores the versatility and potential of our Hypercon technology to enable
small volume, patient-delivered next‑generation biologics," said Helen Torley, President and Chief Executive
Officer of Halozyme. "Vertex is a proven innovator with deep expertise, and we believe Hypercon can play an
important role in supporting improved ease of patient access to targeted biologics that have the potential to
advance innovation for patients with serious diseases."
"We are pleased to add Halozyme's Hypercon drug delivery technology to our toolbox as we pursue transformative
therapies for patients with serious diseases," said Mark Bunnage, D.Phil., Executive Vice President and Chief
Scientific Officer of Vertex Pharmaceuticals. "We look forward to exploring the full potential of this technology
across our programs of interest."
Under the terms of the exclusive agreement, Vertex will make a $15 million upfront payment to Halozyme and
potential future milestone payments. Halozyme will also be entitled to royalties on net sales of products
developed using the Hypercon™ technology.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes
for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the
proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of
injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched
more than one million patient lives through ten commercialized products across over 100 global markets and is
licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie,
Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus
N.V. and Skye Bioscience.
Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf
Bio's hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new
standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and
enabling administration in at‑home and healthcare‑provider settings. The addition of Surf Bio's polymer‑based
hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously,
meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf
Bio's technology complement ENHANZE® by enabling creation and delivery of highly concentrated biologics. The
Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx
and Vertex Pharmaceuticals.
Halozyme also develops, manufactures and commercializes drug-device combination products using advanced
auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient
comfort and adherence. The Company has two proprietary commercial products, Hylenex® and
XYOSTED®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and
McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka
is also the site of its operations facility.
For more information, visit www.halozyme.com and connect with
us on LinkedIn.
Forward-Looking Statements
In addition to historical information, the statements set forth above include forward-looking statements
including, without limitation, statements concerning royalty revenue growth, potential new partnerships and
innovations, the possible benefits and attributes of the Hypercon™ technology, including the potential to reduce
injection volume for the same dosage of drugs and biologics and possibly enabling administration in at‑home and
healthcare‑provider settings and statements concerning certain other potential benefits of the Hypercon™
technology including facilitating administration of injectable medications through subcutaneous delivery by
enabling creation and delivery of highly concentrated biologics and potentially lowering the treatment burden,
easing treatment access and improving the treatment experience for patients. These forward-looking statements also
include statements regarding the product development and commercialization efforts of Hypercon's collaboration
partner (including the potential regulatory approval and launch of such products as a result of such efforts and
the potential future market opportunity for such products) and Hypercon's potential receipt of upfront payments
and payments associated with achievement of certain development, regulatory and sales-based milestones, and
royalties on sales of commercialized products. These forward-looking statements involve risks and uncertainties
that could cause actual results to differ materially from those in the forward-looking statements. The
forward-looking statements are typically, but not always, identified through use of the words "expect," "believe,"
"enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential,"
"possible," "should," "continue" and other words of similar meaning. Actual results could differ materially from
the expectations contained in forward-looking statements as a result of several factors, including risks and
uncertainties concerning whether payments due to Hypercon under the collaboration agreement will be received and
whether development, regulatory and sales-based milestones will be achieved, uncertainties concerning whether
collaborative products are ultimately developed, approved or commercialized and the potential future market for
such products, unexpected levels of revenue growth, expenditures and costs, unexpected results or delays in
development and regulatory review, unexpected regulatory approval requirements, unexpected adverse events or
patient outcomes and competitive conditions. These and other factors that may result in differences are discussed
in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange
Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect
events after the date of this release.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com
Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-appoints-david-ramsay-as-interim-chief-financial-officer-302711900.html
SOURCE Halozyme Therapeutics, Inc.